Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-23
2005-08-23
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S361100
Reexamination Certificate
active
06933311
ABSTRACT:
Compounds of formula (I)are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2and L are as defined in the description.
REFERENCES:
patent: 3647910 (1972-03-01), Kirchner
patent: 3711610 (1973-01-01), Kirchner
patent: 3814711 (1974-06-01), Eloy et al.
patent: 4958026 (1990-09-01), Schoellkopf et al.
patent: 5362878 (1994-11-01), Chang et al.
patent: 5444038 (1995-08-01), James et al.
patent: 5646140 (1997-07-01), Sugg et al.
patent: 5656634 (1997-08-01), Chang et al.
patent: 5760246 (1998-06-01), Biller et al.
patent: 6291476 (2001-09-01), Kordik et al.
patent: 6472414 (2002-10-01), Biller et al.
patent: 6511998 (2003-01-01), Kordik et al.
patent: 6555539 (2003-04-01), Reich et al.
patent: 0 418 071 (1991-03-01), None
patent: 0 609 960 (1994-08-01), None
patent: 1403255 (2004-03-01), None
patent: 1 344 579 (1963-10-01), None
patent: 2 020 280 (1979-11-01), None
patent: 91/13874 (1991-09-01), None
patent: W O 97/26240 (1997-07-01), None
patent: 00/50387 (2000-08-01), None
patent: 02/08221 (2002-01-01), None
patent: 03/014064 (2003-02-01), None
patent: W O 03/22809 (2003-03-01), None
patent: 03/80578 (2003-10-01), None
Lichtenthaler et al., “Nucleosides. 44. Benzo-separated Pyrazolopyrimidines: Expeditious Synthesis of [3,4-g] and [3,4-h]-linked Pyrazoloquinazolinones,”Tetrahedron Letters, 22(44), 4397-4400 (1981).
Nunn et al., “Semmler-Wolff Aromatization and Abnormal Beckmann and Schmidt Reactions of 3-Alkyl-4-oxo-1-phenyl-4,5,6,7-tetrahydroindazoles and Their Oximes in Polyphosphoric Acid,”J. Chem. Soc, Perkin Transactions I, 1973, Issue No. 22, 2697-2703 (1973).
Adams et al., “Dialkylaminoalkylquinolines,” J. Chem. Soc. 3066-3071 (1957).
Berge, et al. “Pharmacutical Salts,”Journal of Pharmaceutical Sciences66:1 et seq. (1977) (Jan., 1977).
Cannon et al., “Synthesis of N-alkyl derivatives of 4-(2'-aminothyl)indole,” J. Heterocyclic Chemistry 19:1195-1199 (1982) (Sep. Oct., 1982).
Caterina, et al., “Impaired Nociception and pain sensation in mice lacking the capsaicin receptor,”Science288:306-313 (2000) (Apr. 14, 2000).
Caterina, et al., “The capsaicin receptor: a heat-activated ion channel in the pain pathway,”Nature389:816-824 (1997) (Oct. 23, 1997).
Caterina, et al., “The Vanilloid Receptor: A Molecular gateway to the pain pathway,”Annual Review of Neuroscience24:487-517 (2001).
Collier, et al., Br. J. Pharmacol. Chemother. 32:295-310 (1968).
Davies, “Indazole Derivatives: The synthesis of various amino- and hydroxy-indazoles and derived sulphonic acids,” J. Chem. Soc. 2412-2423 (1955).
Davis, et al., “Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia,”Nature405:183-187 (2000) (May 11, 2000).
Fieser et al., “A comparison of heterocyclic systems with benzene. VI. Quinines of the quinoline and isoquinoline series,” J. Amer. Chem. Soc. 57:1840-1844 (1935) (Oct., 1935).
Forbes et al., “N-(1-methyl-5-indolyl)-N'-(3-pyridyl)urea hydrochloride: the first selective 5-HT1creceptor antagonist,” J. Med. Chem. 36:1104-1107 (1993).
Fowler, “Intravesical treatment of overactive bladder,”Urology55(Supp 5A):60-64 (2000) (May, 2000).
Gall et al., “171. On a few derivatives of heterocyclic carbonic acids IV. Metal ions and biological action, 36threport,” Helv. Chim. Acta 38(171):1421-1423 (1955) with translation.
Giencke et al. “Desmethyl(trifluormethyl)actinomycine,” Liebigs Ann. Chem. 6:569-579 (1990).
Hayes, et al., “Cloning and functional expression of a human orthologue of rat vanilloid receptor-1,” Pain 88:205-215 (2000).
Honma et al., “Structure-based generation of a new class of potent Cdk4 inhibitors: New de Novo design strategy and library design,” J. Med. Chem. 44:4615-4627 (2001) (WEB Published Dec. 13, 2001).
Kawasaki et al., “A new approach to 4-(2-aminoethyl)indoles via Claisen ortho-amide rearrangement of 3-hydroxy-2-methoxyindolines,” J. Chem. Soc. Chem. Commun. 10:781-782 (1990).
Kumar et al. “Antiparasitic agents: Part XV—synthesis of 2-substituted 1(3)H-imidazo[4,5-ƒ]isoquinolines as anthelmintic agents,” Indian Journal of Chemistry 31B:177-182 (1992) (Mar., 1992).
Lila et al., “Large scale preparation of protected 4-aminomethylbenzamidine. Application to the synthesis of the thrombin inhibitor, melagatran,” Synth. Comm. 28:4419-4429 (1998).
Mooney et al., “Potential antitumor agens, 10. Synthesis and biochemical properties of 5-N-alkylamino-N,N-dialkylamino-, and N-alkylacetamido-1-formylisoquinoline thiosemicarbazones,” Journal of Medicinal Chemistry 17(11):1145-1150 (1974) (Orally presented in part on Aug., 1972).
Mukkala et al., “124. New heteromatic complexing agents and luminescence of their europium (III) and terbium(III) chelates,” Helvetica Chima Acta 75:1621-1632 (1992).
Naruto et al., “Photo-induced Friedel-Crafts reactions. IV>Indoleacetic acids,” Chemical and Pharmaceutical Bulletin, Tokyo, JP 20(10):2163-2171 (1972).
Nolano, et al., “Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation,”Pain81:135-145 (1999).
Prescott, et al.,Methods in Cell Biology, Academic Press, New York, N.Y. vol. 14:33 et seq. (1976), only Chapter 4 (Poste et al.) supplied.
Prijs et al. “9. On a few derivatives of heterocyclic carbonic acids I . . . Metal ions and biological action, 16threport,” Helv. Chim. Acta 37:90-94 (1954) with translation.
Roe et al., “The preparation of heterocyclic fluorine compounds by the schiemann reaction. III. Some monofluoroisoquinolines,” J. Am. Chem. Soc., 73:687-689 (1951) (Feb., 1951).
Sato et al., “Construction of optically pure tryptophans from serine derived aziridine-2-carboxylates,” Tetrahedron Letters 30(31):4073-4076 (1989).
Taurins et al., “Thiazoloisoquinolines. IV. The synthesis and spectra of thiazolo[4,5-h]-and thiazolo[5,4-ƒ]isoquinolines. The ultraviolet and proton magnetic resonance spectra of some substituted isoquinolines,” Canadian Journal of Chemistry 49(24):4054-4061 (1971).
Warpehoski et al., “Stereoelectronic factors influencing the biological activity and DNA interaction of synthetic antitumor agents modeled on CC-1065,” J. Med. Chem. 31:590-603 (1988).
Bayburt Erol K.
DiDomenico, Jr. Stanley
Drizin Irene
Gomtsyan Arthur R.
Koenig John R.
Abbott Laboratories
Crane L. E.
Ferrari-Dileo Gabryleda
Ward Michael J.
Wilson James O.
LandOfFree
Fused azabicyclic compounds that inhibit vanilloid receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused azabicyclic compounds that inhibit vanilloid receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused azabicyclic compounds that inhibit vanilloid receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3499734